Pharmacokinetics and pharmacodynamics of 7α-methyl-19-nortestosterone after intramuscular administration in healthy men

Human Reproduction

Volumn 12, Issue 5, 1997, Pages 967-973

  Suvisaari, Janne ^a   Sundaram, Kalyan ^b   Noé, Gabriela ^c   Kumar, Narender ^b   Aguillaume, Claude ^b   Tsong, Yun Yen ^b   Lähteenmäki, Pekka ^a,d   Bardin, C Wayne ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b POPULATION COUNCIL   (United States)

^c Instituto Chileno de Medicina Reproductiva   (Chile)

^d Vaestoliitto   (Finland)

Author keywords

7 methyl 19 nortestosterone; Androgens; Male contraception; Pharmacokinetics

Indexed keywords

FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; METHYLESTRENOLONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; DRUG DERIVATIVE; NANDROLONE; POSTCOITUS CONTRACEPTIVE AGENT; TRESTOLONE;

ADULT; ARTICLE; CHILE; CLINICAL TRIAL; CONTRACEPTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; FINLAND; FOLLITROPIN BLOOD LEVEL; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NORMAL HUMAN; TESTOSTERONE BLOOD LEVEL; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; METABOLISM; MULTICENTER STUDY; TIME;

ADULT; CHILE; COHORT STUDIES; CONTRACEPTIVES, POSTCOITAL, HORMONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FINLAND; FOLLICLE STIMULATING HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; LUTEINIZING HORMONE; MALE; NANDROLONE; TESTOSTERONE; TIME FACTORS;

EID: 0030610958     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/12.5.967     Document Type: Article

References (13)

1. Agarwal, A.K. and Monder, C. (1988) In-vitro metabolism of 7α-methyl-19-nortestosterone by rat liver, prostate and epididymis. Endocrinology, 123, 2187-2193.
2. Bridges, N.A., Hindmarsh, P.C., Pringle, P.J. et al. (1993) The relationship between endogenous testosterone and gonadotrophin secretion. Clin. Endocrinol (Oxf.), 38, 373-378.
3. Dabbs, J.M. Jr (1990) Age and seasonal variation in serum testosterone concentration among men. Chronobiol. Int., 7, 245-249.
4. Greenblatt, D.J. and Koch-Weser, J. (1975) Clinical pharmacokinetics (two pans). First part: N. Engl. J. Med., 293, 702-705. Second part: N. Engl. J. Med., 293, 964-970.
5. Greenblatt, D.J. and Koch-Weser, J. (1975) Clinical pharmacokinetics (two pans). First part: N. Engl. J. Med., 293, 702-705. Second part: N. Engl. J. Med., 293, 964-970.
6. Kumar, N., Didolkar, A.K., Ladd, A. et al. (1990) Radioimmunoassay of 7α-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. J. Steroid Biochem. Mol. Biol., 37, 587-591.
7. Kumar, N., Didolkar, A.K., Monder, C. et al. (1992) The biological activity of 7α-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology, 130, 3677-3683.
8. O'Brian, R.M. (1966) Preliminary pharmacologic dose-response studies of 7α-methyl-19-nortestosterone (NSC-69948) in patients. Cancer Chemother. Rep., 50, 335-338.
9. Rowland, M. and Tozer, T.N. (1989) Clinical Pharmacokinetics: Concepts and Applications. Lea & Febiger, Philadelphia.
10. Segaloff, A., Weeth, J.B., Cuningham, M. and Meyer, K.K. (1964) Hormonal therapy in cancer of the breast. XXIII. Effect of 7α-methyl-19-nortestosterone acetate and testosterone propionate on clinical course and hormonal excretion. Cancer, 17, 1248-1253.
11. Sufi, S.B., Donaldson, A. and Jeffcoate, S.L. (1990) WHO Matched Reagent Programme Method Manual, 14th edn. World Health Organization, London, pp. 72-80.
12. Sundaram, K., Kumar, N. and Bardin, C.W. (1993) 7α-Methyl-nortestosterone (MENT): The optimal androgen for male contraception. Ann Med., 25, 199-205.
13. Wisser, H. and Breuer, H. (1981) Circadian changes of clinical chemical and endocrinological parameters. J. Clin. Chem. Clin. Biochem., 19, 323-337.